Clinical trials
Craniosynostoses trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Terminated | 5 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Human Genome Research Institute (NHGRI) | 3 |
| Boston Children's Hospital | 2 |
| University of Pittsburgh | 2 |
| University of Texas Southwestern Medical Center | 2 |
| Baylor College of Medicine | 1 |
| Children's National Research Institute | 1 |
| Gary F. Rogers, MD | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Mayo Clinic | 1 |
| Memorial Healthcare System | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Craniosynostoses | 21 |
| Plagiocephaly | 4 |
| Plagiocephaly, Nonsynostotic | 2 |
| Brain Injuries, Traumatic | 1 |
| Congenital Abnormalities | 1 |
| Epilepsy | 1 |
| Hearing Loss | 1 |
| Hemorrhage | 1 |
| Hypovolemia | 1 |
| Tarsal Coalition | 1 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.